RVMD
HEALTHCARERevolution Medicines Inc
$151.07+3.86 (+2.62%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving RVMD Today?
No stock-specific AI insight has been generated for RVMD yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$34.00$155.70
$151.07
Fundamentals
Market Cap$32.1B
P/E Ratio—
EPS$-7.12
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume2.9M
Avg Volume (10D)—
Shares Outstanding212.6M
RVMD News
25 articles- RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense ViewYahoo Finance·May 7, 2026
- Revolution Medicines, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Revolution Medicines Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic CancerGlobeNewswire Inc.·May 6, 2026
- Royalty Pharma Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate ProgressYahoo Finance·May 6, 2026
- How FDA Expanded Access for Daraxonrasib and Phase 3 Survival Data At Revolution Medicines (RVMD) Has Changed Its Investment StoryYahoo Finance·May 6, 2026
- Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?Yahoo Finance·May 4, 2026
- Revolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B OpportunityYahoo Finance·May 2, 2026
- Revolution Medicines Inc. (RVMD): Billionaire Tom Steyer Remains Bullish on This StockYahoo Finance·May 2, 2026
- Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer ResultsYahoo Finance·Apr 30, 2026
- Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026Yahoo Finance·Apr 29, 2026
- Erasca Shares Plunge 48% After Trial Patient Death, Patent Dispute EmergesYahoo Finance·Apr 29, 2026
- Revolution’s on a pancreatic cancer winning streak. What comes next for the biotech?Pharmavoice·Apr 29, 2026
- Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug TrialMotley Fool·Apr 28, 2026
- Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off.Yahoo Finance·Apr 28, 2026
- Why Erasca, Up 415% This Year Amid Revolution-Tied Furor, Just Lost Half Its ValueYahoo Finance·Apr 28, 2026
- Assessing Revolution Medicines (RVMD) Valuation After Positive RASolute 302 And Zoldonrasib Clinical UpdatesYahoo Finance·Apr 28, 2026
- Revolution Medicines Trial Updates Spark Fresh Interest In RAS Focused PipelineYahoo Finance·Apr 28, 2026
- Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It SeemsMotley Fool·Apr 27, 2026
- SCHA vs. ISCB Comes Down to Sector Tilt and Your Drawdown ToleranceThe Motley Fool·Apr 25, 2026
- Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual MeetingGlobeNewswire Inc.·Apr 19, 2026
- IonQ, Oklo, And Robinhood Are Among the Top 10 Large-Cap Gainers Last Week (April 13-April 17): Are the Others in Your Portfolio?Benzinga·Apr 19, 2026
- Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior NotesGlobeNewswire Inc.·Apr 15, 2026
- Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: AnalystBenzinga·Mar 25, 2026
All 25 articles loaded
Price Data
Open$146.72
Previous Close$147.21
Day High$151.43
Day Low$145.29
52 Week High$155.70
52 Week Low$34.00
52-Week Range
$34.00$155.70
$151.07
Fundamentals
Market Cap$32.1B
P/E Ratio—
EPS$-7.12
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume2.9M
Avg Volume (10D)—
Shares Outstanding212.6M
About Revolution Medicines Inc
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—